Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSA-DC Vaccine in Gastrointestinal Solid Tumors
NCT03185429Phase 1Unknown
- Sponsor
- BGI
- Start
- Dec 2017
- Primary completion
- Dec 2018
01
Overview
Phase 1, open-label trial of TSA-DC vaccine in gastric cancer (GC) and colorectal cancer (CRC), sponsored by BGI. Primary endpoints: Safety and tolerance of autologous TSA-DC cell at 1 year and Overall Response Rate at 1 year. Status: unknown.
02
Drugs
TSA-DC vaccine
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03185429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185429.